Lilly to present data for galcanezumab for the prevention of migraine at the AAN annual meeting

Treatment could help to reduce the number of days lost to migraine.

Eli Lilly will highlight Phase II data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place 22-28 April 2017, in Boston.

Lilly will present four abstracts at AAN, including safety and patient outcomes data for galcanezumab in patients with migraine and factors associated with a reduction in monthly migraine headache days among patients with episodic migraine. Lilly will also highlight findings from US healthcare claims data identifying clinical characteristics and treatment patterns among patients with cluster headache.

Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of episodic and chronic migraine and cluster headache. Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache.

"Migraine and cluster headaches are serious, neurological diseases that have a significant physical and emotional impact on not only people affected, but those with whom they interact at home and at work," said Sheena Aurora, medical fellow and global launch leader, galcanezumab, Eli Lilly and Company. "Lilly is excited to present these galcanezumab data, which further our understanding of these diseases and support our decades-long effort to develop a targeted, preventive therapy that can bring significant value to patients, including a meaningful reduction in the number of days lost to migraine."